Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/3536
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBobba, K N-
dc.contributor.authorSaranya, G-
dc.contributor.authorSujai, P T-
dc.contributor.authorJoseph, M M-
dc.contributor.authorVelusamy, N-
dc.contributor.authorPodder, A-
dc.contributor.authorMaiti, K K-
dc.contributor.authorBhuniya, S-
dc.date.accessioned2020-02-25T13:29:52Z-
dc.date.available2020-02-25T13:29:52Z-
dc.date.issued2019-02-20-
dc.identifier.citationACS Applied Bio Materials; 2(3): 1322-1330en_US
dc.identifier.urihttp://10.10.100.66:8080/xmlui/handle/123456789/3536-
dc.description.abstractRealizing the importance of activation of the anticancer drug, its distribution, and for cancer management, a new theranostic probe has been developed. Endogenous H2S stimulated the theranostic molecular prodrug (TP-HS) which is activated in cancer cells; it monitors the actual time of formation of therapeutic agent SN-38 in cellular milieu through fluorescence imaging. Upon exposure to H2S in a similar physiological condition, the azide functionality converted to amine (−NH2) in TP-HS which allows self-immolative scission of the labile benzyl-carbonate moiety for release of rhodol and SN-38 in a concerted manner. Thus, an intense emission band centered at 548 nm has appeared for quantifying the active therapeutic component. The fluorescence image revealed that the TP-HS preferentially releases rhodol and SN-38 in colon cancer (HCT116 cells) and lung cancer cells (A549 cells) compared to normal human fibroblast cells (WI-38). Further, the dose-dependent antiproliferative activity of TP-HS against various cells supports that TP-HS releases SN-38 based on endogenous H2S in cancer cells followed by its apoptotic progression monitored by (a) live–dead, i.e., acridine orange–ethidium bromide double staining assay, (b) APOPercentage apoptotic assay, and (c) Annexin V-FITC staining by flow cytometry. The theranostic prodrug TP-HS showed anticancer efficacy via the desirable apoptotic pathway. It is the first demonstration of a strategic theranostic molecular prodrug system that could be delivered chemotherapeutically with validating the real-time activation of chemotherapy in the cancer cells without the support of a cancer-directing ligand.en_US
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.subjecttheranosticen_US
dc.subjectcystathionine β-synthase (CBS)en_US
dc.subjectSN-38en_US
dc.subjectendogenous H2Sen_US
dc.subjectapoptosisen_US
dc.subjectcancer cellsen_US
dc.titleEndogenous H2S‑Assisted Cancer-Cell-Specific Activation of Theranostics with Emission Readouten_US
dc.typeArticleen_US
Appears in Collections:2019

Files in This Item:
File Description SizeFormat 
Endogenous H2S-Assisted Cancer-Cell-Specific_Kondapa Naidu Bobba_Applied Bio Materials.pdf
  Restricted Access
6 MBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.